Strombaject 50mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Usage

1. Verify the ampoule's printed batch number and expiry date against the carton before use, confirming the intact glass-fusion seal as evidence of unbroken sterility from the Chișinău production line.
2. Snap the ampoule open at the coloured score ring using a sterile gauze pad; this single-use format means the entire 1 ml content must be drawn immediately and the ampoule discarded after use.
3. Draw the full 1 ml (50 mg) into the syringe with an 18–21 gauge drawing needle; because stanozolol suspensions can settle, agitate the ampoule gently before drawing to ensure uniform particle distribution.
4. Switch to an injection needle appropriate for intramuscular delivery (23–25 gauge, 1–1.5 inch) and administer into a large muscle group — gluteus, vastus lateralis, or deltoid — rotating sites across each EOD session to prevent localised irritation.
5. Aspirate briefly before injection as standard intramuscular practice, then administer slowly and steadily; aqueous suspensions can cause transient injection-site discomfort, a characteristic noted in stanozolol's clinical history that is reduced by slow delivery speed.
6. Record date, site, and dose after each injection; this log supports the monitoring of any hepatic enzyme changes at the mid-cycle blood draw, consistent with responsible use protocols recommended across decades of clinical guidance on this compound.

Warnings

Frequently asked questions

Where did stanozolol originally come from and who developed it?

Stanozolol was originally synthesised by chemists at Winthrop Laboratories in 1962 as part of a mid-century programme to create anabolic steroids with reduced androgenic activity compared to testosterone. The compound was patented and later approved by the U.S. FDA under the brand name Winstrol for clinical indications including hereditary angioedema and aplastic anaemia, providing a legitimate regulatory and research foundation from the outset.

When was injectable stanozolol introduced and how does it differ historically from the oral form?

The injectable aqueous suspension form of stanozolol was developed alongside the oral tablet during the early commercial phase of the compound's history, with both forms appearing in clinical practice during the 1960s and 1970s. The injectable route was favoured in settings requiring bypassed first-pass hepatic metabolism, a characteristic that generated separate pharmacokinetic datasets — including plasma half-life measurements of approximately 24 hours — distinct from the oral formulation's metabolic profile.

How has stanozolol's use in athletic and bodybuilding contexts evolved since its development?

Stanozolol's athletic use grew substantially during the 1970s and 1980s, particularly in track-and-field and strength sports, producing an extensive empirical literature on cycle length, SHBG suppression, and lean-mass retention that bodybuilders still reference today. Over decades its use shifted from primarily clinical applications toward performance contexts, and the accumulated long-term data — covering both efficacy endpoints and side-effect profiles — sets it apart from many synthetic androgens developed more recently with far shorter research histories.

Why does Strombaject come in 10x1ml single-dose ampoules rather than a multi-dose vial?

Single-dose glass ampoules eliminate the risk of microbial contamination from repeated needle entry that is inherent in multi-dose vials. Each of the ten ampoules in a Strombaject pack is heat-sealed at the point of filling, and once opened it is intended for immediate single use, ensuring that every injection draws from a sterile, uncontaminated source — a critical consideration for an aqueous suspension, which lacks the antimicrobial preservatives commonly added to oil-based preparations.

Is 50mg/ml stanozolol considered a low concentration, and does that affect dosing accuracy?

At 50 mg/ml, Strombaject sits at the standard concentration for injectable stanozolol preparations and is the lowest concentration tier encountered in this compound category. Far from being a drawback, this concentration level allows straightforward dose increments in 0.5 ml steps — yielding 25 mg per increment — which improves dosing granularity for users calibrating weekly protocols between 50 mg and 100 mg. This aligns with the dose ranges most consistently reported in the clinical and sports-science literature on injectable stanozolol. (2) angle_used

Manufacturer

Strombaject sits within Balkan Pharmaceuticals' injectable anabolic portfolio as one of the company's historically grounded single-compound products — a line built on established molecules with decades of clinical precedent rather than novel or experimental agents. Across this portfolio, Balkan maintains a consistent policy of single active ingredient per SKU, which means Strombaject contains only stanozolol at 50 mg/ml with no secondary anabolic substances, allowing precise dose management consistent with how the compound was characterised in its original clinical trials. The injectable range itself spans aqueous suspensions and oil-based solutions, with each formulation type validated separately under EU GMP Annex 1 parenteral-product requirements at the Chișinău facility; for aqueous products such as Strombaject, this includes particular scrutiny of particle size distribution and suspension homogeneity during in-process quality checks. Balkan's product-line architecture also ensures that every injectable SKU is released only after HPLC confirmation of stated concentration and LAL endotoxin clearance, controls applied uniformly across the portfolio regardless of which active ingredient is involved.